Frequent LOH at Chromosome 12q22-23 and Apaf-1 Inactivation in Glioblastoma

Brain Pathology

Volumn 13, Issue 4, 2003, Pages 431-439

  Watanabe, Takuya ^a   Hirota, Yuichi ^a   Arakawa, Yasuaki ^a   Fujisawa, Hironori ^a   Tachibana, Osamu ^a   Hasegawa, Mitsuhiro ^a   Yamashita, Junkoh ^a   Hayashi, Yutaka ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; GENE PRODUCT; MICROSATELLITE DNA; PROTEIN P53; PROTEINASE;

ADULT; AGED; APOPTOSIS; ARTICLE; CARCINOGENESIS; CHROMOSOME 10P; CHROMOSOME 10Q; CHROMOSOME 11P; CHROMOSOME 12Q; CHROMOSOME 17P; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME 22Q; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE INACTIVATION; GENE MUTATION; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METHYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

EID: 0242667892     PISSN: 10156305     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2003.tb00474.x     Document Type: Article

References (50)

1. Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, You MJ, Tang Y, DeFrances J, Stover E, Weissleder R, Rowitch DH, Louis DN, DePinho RA (2002) Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms, governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1:269-277.
2. Bala S, Oliver H, Renault B, Montgomery K, Dutta S, Rao P, Houldsworth J, Kucherlapati R, Wang X, Chaganti RS, Murty VV (2000) Genetic analysis of the APAF1 gene in male germ cell tumors. Genes Chromosomes Cancer 28:258-268.
3. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG (2001) Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10:687-692.
4. Cecconi F, Gruss P (2001) Apaf1 in developmental aptosis and cancer: how many ways to die? Cell Mol Life Sci 58:1688-1697.
5. Costello JF, Berger MS, Huang HS, Cavenee WK (1996) Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 56:2405-2410.
6. Deen DF, Chiarodo A, Grimm EA, Fike JR, Israel MA, Kun LE, Levin VA, Marton LJ, Packer RJ, Pegg AE, et al., 0167-594x, Congresses (1993) Brain Tumor Working Group Report on the 9th International Conference on Brain Tumor Research and Therapy. Organ System Program, National Cancer Institute. J Neurooncol 16:243-272
7. Ehrlich M (2002) DNA methylation in cancer: too much, but also too little. Oncogene 21:5400-5413.
8. Esteller M, Herman JG (2002) Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 196:1-7.
9. Fu WN, Bertoni F, Kelsey SM, McElwaine SM, Cotter FE, Newland AC, Jia L (2003) Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia. Oncogene 22:451-455.
10. Fujisawa H, Reis RM, Nakamura M, Colella S, Yonekawa Y, Kleihues P, Ohgaki H (2000) Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab Invest 80:65-72.
11. Fulci G, Labuhn M, Maier D, Lachat Y, Hausmann O, Hegi ME, Janzer RC, Merlo A, Van Meir EG (2000) p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 19:3816-3822.
12. Garinis GA, Patrinos GP, Spanakis NE, Menounos PG (2002) DNA hypermethylation: when tumour suppressor genes go silent. Hum Genet 111:115-127.
13. Hawkins N, Norrie M, Cheong K, Mokany E, Ku SL, Meagher A, O'Connor T, Ward R (2002) CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 122:1376-1387.
14. Hayashi Y, Ueki K, Waha A, Wiestler OD, Louis DN, von Deimling A (1997) Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 7:871-875.
15. Hegi ME, zur Hausen A, Ruedi D, Malin G, Kleihues P (1997) Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas. Int J Cancer 73:57-63.
16. Holland EC, Hively WP, DePinho RA, Varmus HE (1998) A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 12:3675-3685.
17. Iwato M, Tachibana O, Tohma Y, Nitta H, Hayashi Y, Yamashita J (2000) Molecular analysis for p53 and mdm2 in intracranial germ cell tumors. Acta Neuropathol (Berl) 99:21-25.
18. Jia L, Srinivasula, SM, Liu FT, Newland AC, Fernandes-Alnemri T, Alnemri ES, Kelsey SM (2001) Apaf-1 protein deficiency confers resistance to cytochrome c-dependent apoptosis in human leukemic cells. Blood 98:414-421.
19. Jones PA (2001) Cancer. Death and methylation. Nature 409:141, 143-144.
20. Kerr JF, Winterford CM, Harmon BV (1994) Apoptosis. Its significance in cancer and cancer therapy. Cancer 73:2013-2026.
21. Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H (2000) Glioblastoma. In: Pathology and Genetics. Tumours of the Nervous System 2nd, Kleihues P, Cavenee WK (eds.), Chapter 1, pp. 29-39,IARC Press, Lyon.
22. Kunwar S, Mohapatra G, Bollen A, Lambom KR, Prados M, Feuerstein BG (2001) Genetic subgroups of anaplastic astrocytomas correlate with patient age and survival. Cancer Res 61:7683-7688.
23. Louis DN (1997) A molecular genetic model of astrocytoma histopathology. Brain Pathol 7:755-764.
24. Louis DN, Gusella JF (1995) A tiger behind many doors: multiple genetic pathways to malignant glioma. Trends Genet 11:412-415.
25. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA (2001) Malignant glioma: genetics and biology of a grave matter. Genes Dev 15:1311-1333.
26. Muller MB, Schmidt MC, Schmidt O, Hayashi Y, Rollbrocker B, Waha A, Fimmers R, Volk B, Warnke P, Ostertag CB, Wiestler OD, von Deimling A (1999) Molecular genetic analysis as a tool for evaluating stereotactic biopsies of glioma specimens. J Neuropathol Exp Neurol 58:40-45.
27. Murty VV, Montgomery K, Dutta S, Bala S, Renault B, Bosl GJ, Kucherlapati R, Chaganti RS (1999) A 3-Mb high-resolution BAC/PAC contig of 12q22 encompassing the 830-kb consensus minimal deletion in male germ cell tumors. Genome Res 9:662-671.
28. Nakamura M, Watanabe T, Klangby U, Asker C, Wiman, K, Yonekawa Y, Kleihues P, Ohgaki H (2001) p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 11:159-168.
29. Ono Y, Tamiya T, Ichikawa T, Kunishio K, Matsumoto K, Furuta T, Ohmoto T, Ueki K, Louis DN (1996) Malignant astrocytomas, with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. J Neuropathol Exp Neurol 55:1026-1031.
30. Rasheed BK, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DD, Bigner SH (1994) Alterations of the TP53 gene in human gliomas. Cancer Res 54:1324-1330.
31. Robles AI, Bemmels NA, Foraker AB, Harris CC (2001) APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res 61:6660-6664.
32. Rollbrocker B, Waha A, Louis DN, Wiestler OD, von Deimling A (1996) Amplification of the cyclin-dependent kinase 4 (CDK4) gene is associated with high cdk4 protein levels in glioblastoma multiforme. Acta Neuropathol (Berl) 92:70-74.
33. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B, Wiestler OD, Louis DN, Fimmers R, von Deimling A (2002) Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 61:321-328.
34. Shinoura N, Sakurai S, Shibasaki F, Asai A, Kirino T, Hamada H (2002) Co-transduction of Apaf-1 and caspase-9 highly enhances p53-mediated apoptosis in gliomas. Br J Cancer 86:587-595.
35. Skotheim RI, Diep CB, Kraggerud SM, Jakobsen KS, Lothe RA (2001) Evaluation of loss of heterozygosity/allelic imbalance scoring in tumor DNA. Cancer Genet Cytogenet 127:64-70.
36. Soengas MS, Alarcon RM, Yoshida H, Giaccia AJ, Hakem R, Mak TW, Lowe SW (1999) Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 284:156-159.
37. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW (2001) Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409:207-211.
38. Steinbach JP, Supra P, Huang HJ, Cavenee WK, Weller M (2002) CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity, Brain Pathol 12:12-20.
39. Sung T, Miller DC, Hayes RL, Alonso M, Yee H, Newcomb EW (2000) Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol 10:249-259.
40. Tohma Y, Gratas C, Van Meir EG, Desbaillets I, Tenan M, Tachibana O, Kleihues P, Ohgaki H (1998) Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. J Neuropathol Exp Neurol 57:239-245.
41. Tong CY, Zheng, PP, Pang JC, Poon WS, Chang AR, Ng HK (2001) Identification of novel regions of allelic loss in ependymomas by high-resolution allelotyping with 384 microsatellite markers. J Neurosurg 95:9-14.
42. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN (1996) CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56:150-153.
43. von Deimling A, Fimmers R, Schmidt MC, Bender B, Fassbender F, Nagel J, Jahnke R, Kaskel P, Duerr EM, Koopmann J, Maintz D et al (2000) Comprehensive allelotype and genetic anaysis of 466 human nervous system tumors. J Neuropathol Exp Neurol 59:544-558.
44. von Deimling A, Louis DN, Wiestler OD (1995) Molecular pathways in the formation of gliomas. Glia 15:328-338.
45. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN, 1015-6305, Article J (1993) Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3:19-26.
46. Waha A, Rollbrocker B, Wiestler OD, von Deimling A (1996) A polymerase chain reaction-based assay for the rapid detection of gene amplification in human tumors. Diagn Mol Pathol 5:147-150.
47. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H, 1015-6305, Article J (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6:217-223; discussion 223-214.
48. Wooten EC, Fults D, Duggirala R, Williams K, Kyritsis AP, Bondy ML, Levin VA, O'Connell P (1999) A study of loss of heterozygosity at 70 loci in anaplastic astrocytoma and glioblastoma multiforme with implications for tumor evolution. Neuro-oncol 1:169-176.
49. Zornig M, Hueber A, Baum W, Evan G (2001) Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 1551:F1-37.
50. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X (1997) Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90:405-413.